Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 2 Published - 14:00 UTC    08:00 EST    16-January-2001      
Issue 16 Next Update - 14:00 UTC 08:00 EST    17-January-2001      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya FDA Grants Tiazofurin Orphan-Drug Status

For The Treatment Of Chronic Myelogenous Leukemia


The US Food and Drug Administration (FDA) has granted orphan-drug status designation to the investigational drug Tiazole(TM) (tiazofurin) for the treatment of chronic myelogenous leukemia (CML) in accelerated phase or blast crisis.

Orphan-drug status designation is granted for rare diseases or conditions which affect fewer than 200,000 people in the United States. CML is not currently curable with conventional chemotherapy or immunotherapy. Such status provides 7 years of marketing exclusivity after approval.

Discovered and developed by ICN Pharmaceuticals, Inc., the anti-cancer compound tiazofurin is currently being tested in patients with chronic myelogenous leukemia in accelerated phase or blast crisis, ovarian cancer, and multiple myeloma. In early studies, tiazofurin was found to have activity in patients with CML with blast crisis in clinical trials sponsored by the US National Cancer Institute (NCI).

Tiazofurin is currently in Phase II/III clinical trials. Upon successful completion of required studies and tests, ICN intends to file a New Drug Application (NDA) with the FDA for treatment of CML with blast crisis. For more information, visit the website of ICN Pharmaceuticals at

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.